Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.

Article  CAS  Google Scholar 

Tomey MI, Winston JA. Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health. Ann Glob Health. 2014;80(1):69–76.

Article  Google Scholar 

Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296(11):1377–84.

Article  CAS  Google Scholar 

Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70(11):2021–30.

Article  CAS  Google Scholar 

Szummer K, Lundman P, Jacobson SH, Schön S, Lindbäck J, Stenestrand U, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med. 2010;268(1):40–9.

Article  CAS  Google Scholar 

Bagai A, Lu D, Lucas J, Goyal A, Herzog CA, Wang TY, et al. Temporal trends in utilization of cardiac therapies and outcomes for myocardial infarction by degree of chronic kidney disease: a report from the NCDR chest pain–MI registry. J Am Heart Assoc. 2018;7(24).

Article  Google Scholar 

•• Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144(22):e368–454. Updated multisociety guidelines provide a comprehensive approach to evaluation of the patient with chest pain, with key implications for accurate diagnosis of ACS in CKD patients.

Google Scholar 

Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.

Google Scholar 

K/DOQI clinical practice guidelines for chronic kidney disease. evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.

Google Scholar 

Go AS, Bansal N, Chandra M, Lathon PV, Fortmann SP, Iribarren C, et al. Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. J Am Coll Cardiol. 2011;58(15):1600–7.

Article  Google Scholar 

Sosnov J, Lessard D, Goldberg RJ, Yarzebski J, Gore JM. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis. 2006;47(3):378–84.

Article  Google Scholar 

Rizk DV, Gutierrez O, Levitan EB, McClellan WM, Safford M, Soliman EZ, et al. Prevalence and prognosis of unrecognized myocardial infarctions in chronic kidney disease. Nephrol Dial Transplant. 2012;27(9):3482–8.

Article  CAS  Google Scholar 

Braghieri L, Badwan OZ, Skoza W, Fares M, Menon V. Evaluating troponin elevation in patients with chronic kidney disease and suspected acute coronary syndrome. Cleve Clin J Med. 2023;90(8):483–9.

Article  Google Scholar 

Banerjee D, Perrett C, Banerjee A. Troponins, acute coronary syndrome and renal disease: from acute kidney injury through end-stage kidney disease. Eur Cardiol. 2019;14(3):187–90.

Article  Google Scholar 

Gallacher PJ, Miller-Hodges E, Shah ASV, Anand A, Dhaun N, Mills NL, et al. Use of high-sensitivity cardiac troponin in patients with kidney impairment: a randomized clinical trial. JAMA Intern Med. 2021;181(9):1237–9.

Article  Google Scholar 

Jaffe AS, Ritter C, Meltzer V, Harter H, Roberts R. Unmasking artifactual increases in creatine kinase isoenzymes in patients with renal failure. J Lab Clin Med. 1984;104(2):193–202.

CAS  Google Scholar 

Alvin MD, Jaffe AS, Ziegelstein RC, Trost JC. Eliminating creatine kinase–myocardial band testing in suspected acute coronary syndrome: a value-based quality improvement. JAMA Intern Med. 2017;177(10):1508–12.

Article  Google Scholar 

Pandey AK, Duong T, Swiatkiewicz I, Daniels LB. A comparison of biomarker rise in type 1 and type 2 myocardial infarction. Am J Med. 2020;133(10):1203–8.

Article  CAS  Google Scholar 

Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the HEART score. Neth Heart J. 2008;16(6):191–6.

Article  CAS  Google Scholar 

Shafi S, Saleem M, Anjum R, Abdullah W, Shafi T. ECG abnormalities in patients with chronic kidney disease. J Ayub Med Coll Abbottabad. 2017;29(1):61–4.

Google Scholar 

Masoudi FA, Plomondon ME, Magid DJ, Sales A, Rumsfeld JS. Renal insufficiency and mortality from acute coronary syndromes. Am Heart J. 2004;147(4):623–9.

Article  Google Scholar 

Keough-Ryan TM, Kiberd BA, Dipchand CS, Cox JL, Rose CL, Thompson KJ, et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. Am J Kidney Dis. 2005;46(5):845–55.

Article  Google Scholar 

Hira RS. Care of patients with chronic kidney disease presenting with acute coronary syndrome: improved, but not good enough. J Am Heart Assoc. 2018;7(24): e011254.

Article  Google Scholar 

Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non–ST-segment elevation myocardial infarction in patients with chronic kidney disease. Circulation. 2010;121(3):357–65.

Article  CAS  Google Scholar 

Chertow GM, Normand S-LT, McNeil BJ. “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol. 2004;15(9):2462–8.

Article  Google Scholar 

Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE quality improvement initiative. JAMA. 2004;292(17):2096–104.

Article  CAS  Google Scholar 

James MT, Tonelli M, Ghali WA, Knudtson ML, Faris P, Manns BJ, et al. Renal outcomes associated with invasive versus conservative management of acute coronary syndrome: propensity matched cohort study. BMJ. 2013;347: f4151.

Article  Google Scholar 

Weisbord SD, Palevsky PM, Kaufman JS, Wu H, Androsenko M, Ferguson RE, et al. Contrast-associated acute kidney injury and serious adverse outcomes following angiography. J Am Coll Cardiol. 2020;75(11):1311–20.

Article  Google Scholar 

• Wilson TA, Hazlewood GS, Sajobi TT, Wilton SB, Pearson WE, Connolly C, et al. Preferences of patients with chronic kidney disease for invasive versus conservative treatment of acute coronary syndrome: a discrete choice experiment. J Am Heart Assoc. 2023;12(6):e028492. This analysis provides unique insight into the values and preferences of patients with CKD with regard to risks and benefits of management for ACS. 

Article  Google Scholar 

Washam JB, Herzog CA, Beitelshees AL, Cohen MG, Henry TD, Kapur NK, et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation. 2015;131(12):1123–49.

Article  Google Scholar 

Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140(3):240–61.

Article  Google Scholar 

• Stefanini GG, Briguori C, Cao D, Baber U, Sartori S, Zhang Z, et al. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J. 2021;42(45):4683–93. This subgroup analysis of the TWLIGHT study offers insight into the candidacy of CKD patients for transition to ticagrelor monotherapy after PCI, including for ACS.

Article  CAS  Google Scholar 

Franchi F, James SK, Lakic TG, Budaj AJ, Cornel JH, Katus HA, et al. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y₁₂ receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. J Am Heart Assoc. 2019;8(6): e011139.

Article  Google Scholar 

Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, et al. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol. 2020;19(1):179.

Article  CAS  Google Scholar 

Gremmel T, Müller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant. 2013;28(8):2116–22.

Article  CAS  Google Scholar 

Baber U, Bander J, Karajgikar R, Yadav K, Hadi A, Theodoropolous K, et al. Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost. 2013;110(1):118–23.

Article  CAS  Google Scholar 

Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, Ferreiro JL, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol. 2010;55(11):1139–46.

Article  CAS  Google Scholar 

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

Article  CAS  Google Scholar 

James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056–67.

Article  Google Scholar 

Rymer JA, Kaltenbach LA, Doll JA, Messenger JC, Peterson ED, Wang TY. Safety of dual-antiplatelet therapy after myocardial infarction among patients with chronic kidney disease. J Am Heart Assoc. 2019;8(10): e012236.

Article  CAS  Google Scholar 

Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012;125(21):2649–61.

Article  Google Scholar 

Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, et al. Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis. Clin J Am Soc Nephrol. 2019;14(6):810–22.

Article  Google Scholar 

Spinler SA, Mahaffey KW, Gallup D, Levine GN, Ferguson JJ 3rd, Rao SV, et al. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol. 2010;144(1):36–41.

Article  Google Scholar 

Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146(1):33–41.

Article  CAS  Google Scholar 

Fox KA, Antman EM, Montalescot G, Agewall S, SomaRa